Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, today announced the appointment of ...

Conference Call and Webcast Information Date: Thursday, November 13, 2025 Time: 4:30 p.m. ET Webcast Link: BioAtla Third Quarter 2025 Earnings Conference Call Dial-in Numbers: (800)-343-4136 (domestic ...

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at A replay of the fireside chat will be available on the Ardelyx ...

A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has ...

PALO ALTO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced the appointment of Kael Reicin to the role of Chief ...

Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory ...

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...

Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note GARDEN CITY, N.Y., Nov. 05, 2025 ...

Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs prescribed VIZZ, 40% of which have prescribed multiple times, resulting in over 5,000 ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter of 2025 and provided a ...

Financial Results for the Quarter Ended September 30, 2025 For the quarter ended September 30, 2025, Vera Therapeutics reported a net loss of $80.3 million, or a net loss per diluted share of $1.26, ...